Patterson Companies Reports Fiscal 2024 Fourth Quarter and Year End Operating Results

Rhea-AI Summary

Patterson Companies reported a slight increase in fiscal 2024 Q4 net sales to $1.72 billion, with internal sales down 0.5%. Dental consumables grew 3.7%, while the Animal Health segment saw a 2.5% rise. GAAP earnings were $0.74 per share; adjusted earnings were $0.82 per share, slightly impacted by a cybersecurity attack. Fiscal 2024 full-year net sales totaled $6.57 billion, up 1.5%, with GAAP earnings of $1.98 per share and adjusted earnings of $2.30 per share. Fiscal 2025 guidance projects GAAP earnings of $2.00-$2.10 per share and adjusted earnings of $2.33-$2.43 per share. The company returned $327.9 million to shareholders through dividends and share repurchases.

Positive

• Fourth-quarter net sales increased to $1.72 billion, up 0.1% year-over-year.
• Dental consumables sales grew 3.7% year-over-year in Q4.
• Animal Health segment internal sales increased 2.5% year-over-year in Q4.
• Full-year net sales for fiscal 2024 totaled $6.57 billion, up 1.5%.
• Returned $327.9 million to shareholders in fiscal 2024 through dividends and share repurchases.
• Fiscal 2025 GAAP earnings guidance set at $2.00 to $2.10 per share.
• Fiscal 2025 adjusted earnings guidance set at $2.33 to $2.43 per share.

Negative

• Internal sales decreased 0.5% in Q4.
• Q4 internal sales of dental equipment decreased 11.9% year-over-year.
• Q4 internal sales of value-added services decreased 11.0% year-over-year.
• Cybersecurity attack on Change Healthcare negatively impacted Q4 earnings by $0.04 per share.
• Full-year GAAP earnings dropped to $1.98 per share from $2.12 per share in fiscal 2023.
• Full-year adjusted earnings dropped to $2.30 per share from $2.42 per share in fiscal 2023.
• Free cash flow declined by $8.6 million year-over-year due to increased capital spending.

Insights

Financial Analyst

Patterson Companies' fiscal 2024 fourth quarter results present a mixed bag for investors. On one hand, $1.72 billion in net sales marks a 0.1% increase compared to the previous year, indicating stagnation. Internal sales fell by 0.5%, driven down by lower equipment sales and the $0.04 per diluted share impact of a cybersecurity attack on Change Healthcare. This suggests areas where the company may need to improve operational resilience.

On the positive side, the company returned $327.9 million to shareholders through dividends and share repurchases, showcasing strong commitment to shareholder value. Despite the challenges, Patterson delivered $0.74 GAAP earnings per share and $0.82 adjusted earnings. The forward guidance for fiscal 2025, projecting GAAP earnings between $2.00 and $2.10 per diluted share and adjusted earnings between $2.33 and $2.43 per diluted share, indicates cautious optimism.

While the earnings and sales growth rates are modest, the substantial capital returns and clear guidance provide some stability and predictability for investors. It's important to watch how the company navigates these operational challenges and cybersecurity risks moving forward.

Market Research Analyst

When examining Patterson Companies' performance, it's evident that differentiation in its business segments is key. The dental segment saw internal sales of consumables increase by 3.7%, while equipment sales fell sharply by 11.9%. This disparity signals a reliance on consumables over higher-margin equipment.

In the animal health segment, internal sales grew by 2.5%, driven by production animal business strength. This segment might be less volatile and offers a steadier growth path compared to dental. Also noteworthy is the 15% rise in value-added services within the animal health segment, which could present a future growth lever.

The company's future guidance is conservative, which may indicate an awareness of potentially continued operational headwinds. Investors should observe the balance between consumable sales stability and equipment sales volatility, as well as the resilience of animal health services amidst market fluctuations.

Tech Expert

The mention of a cybersecurity attack causing a $0.04 hit on diluted earnings per share indicates a vulnerability that could undermine investor confidence. In today’s business landscape, robust cybersecurity measures are non-negotiable. The impact on Change Healthcare shows that even indirect attacks can have significant financial consequences.

For retail investors, it’s important to understand that cybersecurity risks can disrupt not just operational flow but also financial performance. Patterson Companies should strengthen its cybersecurity framework to mitigate such risks and reassure stakeholders of its digital robustness. Monitoring the company's investments in this area could serve as a good indicator of its long-term resilience.

• Fourth quarter reported net sales increased 0.1 percent year-over-year to $1.72 billion, and internal sales decreased 0.5 percent.
• Fourth quarter internal sales benefitted from strong growth in production animal as well as dental consumables growth of 3.7 percent year-over-year.
• Returned $327.9 million to shareholders in fiscal 2024 through dividends and share repurchases.
• Delivered fourth quarter GAAP earnings of $0.74 per diluted share and adjusted earnings¹ of $0.82 per diluted share; both GAAP and adjusted earnings¹ were negatively impacted by $0.04 per diluted share due to the cybersecurity attack on Change Healthcare.
• Achieved fiscal 2024 GAAP earnings of $1.98 per diluted share and adjusted earnings of $2.30 per diluted share.
• Issues fiscal 2025 GAAP earnings guidance of $2.00 to $2.10 per diluted share and adjusted earnings¹ guidance of $2.33 to $2.43 per diluted share.

ST. PAUL, Minn.--(BUSINESS WIRE)-- Patterson Companies, Inc. (Nasdaq: PDCO) today reported operating results for its fiscal 2024 fourth quarter ended April 27, 2024.

"Throughout fiscal 2024, Patterson navigated a challenging market environment while continuing to make progress on our strategic objectives to better position the organization for the future," said Don Zurbay, President and CEO of Patterson Companies. "Our fourth quarter results were driven by strong performances in our dental consumables and production animal businesses, reflecting the strength of Patterson's value proposition across our resilient end markets and our sustained focus on serving as indispensable partners to our customers. Our outlook reflects the continued confidence in our strategy focused on investing to drive enhanced growth and profitability over the long term combined with the current conditions in our end markets.”

Fourth Quarter Fiscal 2024 Results

Consolidated net sales were $1.72 billion (see attached Sales Summary for further details), an increase of 0.1 percent compared to the same period last year. Internal sales, which are adjusted for the effects of currency translation and the net impact of an interest rate swap, decreased 0.5 percent over the prior year period.

Reported net income attributable to Patterson Companies, Inc. for the fourth quarter of fiscal 2024 was $67.0 million, or $0.74 per diluted share, compared to $75.0 million, or $0.77 per diluted share, in the fourth quarter of fiscal 2023. Adjusted net income¹ attributable to Patterson Companies, Inc., which excludes deal amortization, totaled $74.4 million for the fourth quarter of fiscal 2024, or $0.82 per diluted share, compared to $82.4 million, or $0.84 per diluted share, in the fourth quarter of fiscal 2023. The year-over-year decrease in reported and adjusted net income attributable to Patterson Companies, Inc. in the fourth quarter of fiscal 2024 is primarily due to lower sales of equipment and the negative impact of the widely reported cybersecurity attack on vendor partner, Change Healthcare, within the value-added services category of the dental segment. Both reported and adjusted net income in the fiscal 2024 fourth quarter were negatively impacted by $0.04 per diluted share due to the cybersecurity attack on Change Healthcare.

Patterson Dental

Reported net sales in the Dental segment for the fourth quarter of fiscal 2024 were $657.8 million. Internal sales decreased 3.8 percent compared to the fiscal 2023 fourth quarter. Internal sales of consumables increased 3.7 percent year-over-year. Excluding the deflationary impact of certain infection control products, internal sales of consumables increased 4.4 percent year-over-year. Compared to the prior year period, internal sales of equipment decreased 11.9 percent. Internal sales of value-added services decreased 11.0 percent compared to the prior year period, primarily due to the negative impact of the cybersecurity attack on Change Healthcare.

Patterson Animal Health

Reported net sales in the Animal Health segment for the fourth quarter of fiscal 2024 were $1.06 billion. Internal sales growth of 2.5 percent year-over-year was driven by sales growth in the production animal business. Compared to the prior year period, internal sales of consumables grew 2.5 percent, equipment decreased 4.0 percent and value-added services increased 15.0 percent.

Balance Sheet and Capital Allocation

During fiscal 2024, Patterson Companies used $789.4 million of cash from operating activities and collected deferred purchase price receivables of $1.03 billion, generating $238.9 million in cash, compared to generating $244.1 million during fiscal 2023. Free cash flow¹ (see definition below and attached free cash flow table) during fiscal 2024 declined by $8.6 million compared to the fiscal 2023 period due to operational performance and an increased level of capital spending during fiscal 2024.

In the fourth quarter of fiscal 2024, Patterson Companies declared a quarterly cash dividend of $0.26 per share, returning $23.3 million in cash dividends to shareholders. Also, under a prior repurchase authorization, the company repurchased approximately 0.5 million shares during the fiscal fourth quarter. At of the end of fiscal 2024, Patterson had approximately $500 million of share repurchase authority remaining on its current share repurchase authorization. During fiscal 2024, Patterson Companies returned $327.9 million to shareholders in the form of cash dividends and share repurchases.

Fiscal 2024 Full Year Results

Consolidated reported net sales for fiscal 2024 totaled $6.57 billion, a 1.5 percent year-over-year increase. Internal sales for fiscal 2024, which are adjusted for the effects of currency translation, contributions from recent acquisitions and the net impact of an interest rate swap, increased 0.8 percent year-over-year. Fiscal 2024 Dental segment internal sales were flat compared to the prior fiscal year, including a 4.4 percent increase in consumables, a 6.9 percent decline in equipment and a 0.8 percent decrease in value-added services. Fiscal 2024 Animal Health segment internal sales increased 1.3 percent, including 0.8 percent growth in consumables, a 3.3 percent decline in equipment and a 42.6 percent increase in value-added services.

Reported net income attributable to Patterson Companies, Inc. in fiscal 2024 was $185.9 million, or $1.98 per diluted share, compared to $207.6 million, or $2.12 per diluted share in fiscal 2023. Adjusted net income¹ attributable to Patterson Companies, Inc., which excludes deal amortization, totaled $215.3 million, or $2.30 per diluted share, compared to $236.4 million, or $2.42 per diluted share, in the prior year.

Fiscal 2025 Guidance

Patterson Companies today initiated its fiscal 2025 earnings guidance, which is provided on both a GAAP and non-GAAP adjusted¹ basis:

• GAAP earnings are expected to be in the range of $2.00 to $2.10 per diluted share.
• Non-GAAP adjusted earnings¹ are expected to be in the range of $2.33 to $2.43 per diluted share.
• Our non-GAAP adjusted earnings¹ guidance excludes the after-tax impact of:
  • Deal amortization expenses of approximately $29.1 million ($0.33 per diluted share).

Our guidance reflects the strength of our business and competitive positioning as well as completed and previously announced acquisitions. It does not include the impact of unplanned share repurchases, potential future acquisitions or similar transactions, impairments, restructuring and integration expenses not previously publicly disclosed, or amortization expense of acquired intangible assets. Our guidance assumes North American and international end market conditions consistent with current market conditions.

¹Non-GAAP Financial Measures

The term “internal sales” used in this release represents net sales adjusted for the effects of currency translation, contributions from recent acquisitions and the net impact of an interest rate swap. Foreign currency impact represents the difference in results that is attributable to fluctuations in currency exchange rates the company uses to convert results for all foreign entities where the functional currency is not the U.S. dollar. The company calculates the impact as the difference between the current period results translated using the current period currency exchange rates and using the comparable prior period’s currency exchange rates. The company believes the disclosure of net sales excluding the impact of foreign currency, an interest rate swap and recent acquisitions provides useful supplementary information to investors in light of fluctuations in these variables that are independent of our period-over-period performance.

The term “free cash flow” used in this release is defined as net cash used in operating activities less capital expenditures plus the collection of deferred purchase price receivables.

The Reconciliation of GAAP to non-GAAP Measures table appearing behind the accompanying financial information is provided to adjust reported GAAP measures, namely net sales, gross profit, operating expenses, operating income, other income (expense), net, income before taxes, income tax expense, net income, net loss attributable to noncontrolling interests, net income attributable to Patterson Companies, Inc., and diluted earnings per share attributable to Patterson Companies, Inc. for the impact of deal amortization and an interest rate swap along with any related tax effects of these items.

• Deal amortization represents non-cash intangible amortization expense, primarily related to the acquisition of Animal Health International.
  
  
• Interest rate swap -- Our customer financing net sales include the impact of changes in interest rates on deferred purchase price receivables, as the average interest rate in our contract portfolio may not fluctuate at the same rate as interest rate markets, resulting in an increase or reduction of gain on contract sales.
  
  We enter into an interest rate swap to hedge a portion of the related interest rate risk. These agreements do not qualify for hedge accounting, and the gains or losses on an interest rate swap are reported in other income and expense in our condensed consolidated statements of operation and other comprehensive income.
  
  We present a non-GAAP adjustment to reclassify the mark-to-market adjustment on the interest rate swap from other income (expense) to net sales to align the swap impact with the impact on customer financing net sales. We believe adjusted net sales, adjusted gross profit and adjusted operating income, which include the gains and losses on the interest rate swap, provides additional comparability from period to period because they present the impact of interest rate fluctuations, net of the mark-to-market swap adjustment, within adjusted net sales. We note the net impact of interest rate fluctuations has a minimal impact on net income.

Management believes that these non-GAAP measures may provide a helpful representation of the company’s performance and enable comparison of financial results between periods where certain items may vary independent of business performance. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures.

Fourth Quarter Conference Call and Replay

Patterson Companies’ fiscal 2024 fourth quarter conference call will start at 8:30 a.m. Eastern today. Investors can listen to a live webcast of the conference call at www.pattersoncompanies.com. The conference call will be archived on the Patterson Companies website. A replay of the fiscal 2023 fourth quarter conference call can be heard for one week at 1-800-770-2030 and by providing the Conference ID 67281 when prompted.

About Patterson Companies Inc.

Patterson Companies Inc. (Nasdaq: PDCO) connects dental and animal health customers in North America and the U.K. to the latest products, technologies, services and innovative business solutions that enable operational and professional success. Our comprehensive portfolio, distribution network and supply chain is equaled only by our dedicated, knowledgeable people who deliver unrivalled expertise and unmatched customer service and support.

Learn more: pattersoncompanies.com

This press release contains, and our officers and representatives may from time to time make, certain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding future financial performance, and the objectives and expectations of management. Forward-looking statements often include words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “seeks” or words of similar meaning, or future or conditional verbs, such as “will,” “should,” “could” or “may.”

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements.

Any number of factors could affect our actual results and cause such results to differ materially from those contemplated by any forward-looking statements, including, but not limited to, the following: our dependence on suppliers to manufacture and supply substantially all of the products we sell; potential disruption of distribution capabilities, including service issues with third-party shippers; our dependence on relationships with sales representatives and service technicians to retain customers and develop business; risks of selling private label products, including the risk of adversely affecting our relationships with suppliers; adverse changes in supplier rebates or other purchasing incentives; the risk of technological and market obsolescence for the products we sell; the risk of failing to innovate and develop new and enhanced software and e-services products; our dependence on positive perceptions of Patterson’s reputation; risks associated with illicit human use of pharmaceutical products we distribute; risks inherent in acquiring and disposing of assets or other businesses and risks inherent in integrating acquired businesses; turnover or loss of key personnel or highly skilled employees; risks associated with information systems, software products and cyber-security attacks; risks inherent in our growing use of AI systems to automate processes and analyze data; adverse impacts of wide-spread public health concerns as we experienced with the COVID-19 pandemic and may experience in the future; risks related to climate change; our ability to comply with restrictive covenants and other limits in our credit agreement; the risk that our governing documents and Minnesota law may discourage takeovers and business combinations; the effects of the highly competitive dental and animal health supply markets in which we compete; the effects of consolidation within the dental and animal health supply markets; risks from the formation or expansion of GPOs, provider networks and buying groups that may place us at a competitive disadvantage; exposure to the risks of the animal production business, including changing consumer demand, the cyclical livestock market, weather conditions, the availability of natural resources and other factors outside our control, and the risks of the companion animal business, including the possibility of disease adversely affecting the pet population; exposure to the risks of the health care industry, including changes in demand due to political, economic and regulatory influences and other factors outside our control; increases in over-the-counter sales and e-commerce options; risks of litigation and government inquiries and investigations, including the diversion of management’s attention, the cost of defending against such actions, the possibility of damage awards or settlements, fines or penalties, or equitable remedies (including but not limited to the revocation of or non-renewal of licenses) and inherent uncertainty; failure to comply with health care fraud or other laws and regulations; change and uncertainty in the health care industry; failure to comply with existing or future U.S. or foreign laws and regulations including those governing the distribution of pharmaceuticals and controlled substances; failure to comply with evolving data privacy laws and regulations; tax legislation; risks inherent in international operations, including currency fluctuations; and uncertain macro-economic conditions, including inflationary pressures.

The order in which these factors appear should not be construed to indicate their relative importance or priority. We caution that these factors may not be exhaustive, accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results.

You should carefully consider these and other relevant factors, including those risk factors in Part I, Item 1A, (“Risk Factors”) in our most recent Form 10-K and information which may be contained in our other filings with the U.S. Securities and Exchange Commission, or SEC, when reviewing any forward-looking statement.

Investors should understand it is impossible to predict or identify all such factors or risks. As such, you should not consider the foregoing list, or the risks identified in our SEC filings, to be a complete discussion of all potential risks or uncertainties.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We do not undertake any obligation to release publicly any revisions to any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

PATTERSON COMPANIES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited)
	Three Months Ended								Twelve Months Ended
	April 27, 2024				April 29, 2023				April 27, 2024				April 29, 2023
Net sales	$	1,722,660			$	1,721,152			$	6,568,272			$	6,471,471
Gross profit		371,155				389,761				1,380,242				1,372,945
Operating expenses		283,368				284,651				1,127,318				1,096,974
Operating income		87,787				105,110				252,924				275,971
Other income (expense):
Other income, net		12,389				4,747				35,039				27,826
Interest expense		(13,031	)			(10,798	)			(44,910	)			(33,636	)
Income before taxes		87,145				99,059				243,053				270,161
Income tax expense		20,204				24,217				57,534				63,563
Net income		66,941				74,842				185,519				206,598
Net loss attributable to noncontrolling interests		(95	)			(123	)			(412	)			(959	)
Net income attributable to Patterson Companies, Inc.	$	67,036			$	74,965			$	185,931			$	207,557
Earnings per share attributable to Patterson Companies, Inc.:
Basic	$	0.75			$	0.77			$	2.00			$	2.14
Diluted	$	0.74			$	0.77			$	1.98			$	2.12
Weighted average shares:
Basic		89,613				97,224				92,969				97,027
Diluted		90,227				97,768				93,679				97,815
Dividends declared per common share	$	0.26			$	0.26			$	1.04			$	1.04

PATTERSON COMPANIES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited)
	April 27, 2024			April 29, 2023
ASSETS
Current assets:
Cash and cash equivalents	$	114,462		$	159,669
Receivables, net		547,287			477,384
Inventory		782,898			795,072
Prepaid expenses and other current assets		334,116			351,011
Total current assets		1,778,763			1,783,136
Property and equipment, net		229,081			212,283
Operating lease right-of-use assets, net		122,295			92,956
Goodwill and identifiable intangibles, net		349,589			388,293
Investments		166,320			160,022
Long-term receivables, net and other		250,684			242,456
Total assets	$	2,896,732		$	2,879,146
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	745,375		$	724,993
Other accrued liabilities		245,610			250,949
Operating lease liabilities		32,815			28,390
Current maturities of long-term debt		122,750			36,000
Borrowings on revolving credit		186,000			45,000
Total current liabilities		1,332,550			1,085,332
Long-term debt		328,911			451,231
Non-current operating lease liabilities		92,464			67,376
Other non-current liabilities		141,075			156,672
Total liabilities		1,895,000			1,760,611
Stockholders' equity		1,001,732			1,118,535
Total liabilities and stockholders' equity	$	2,896,732		$	2,879,146

PATTERSON COMPANIES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited)
	Twelve Months Ended
	April 27, 2024				April 29, 2023
Operating activities:
Net income	$	185,519			$	206,598
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization		88,156				83,704
Stock-based compensation		17,871				15,543
Non-cash losses (gains) and other, net		204				654
Change in assets and liabilities:
Receivables		(1,102,618	)			(1,047,075	)
Inventory		11,039				(11,086	)
Accounts payable		21,343				43,095
Accrued liabilities		(2,788	)			(21,714	)
Other changes from operating activities, net		(8,104	)			(24,571	)
Net cash used in operating activities		(789,378	)			(754,852	)
Investing activities:
Additions to property and equipment and software		(67,626	)			(64,220	)
Collection of deferred purchase price receivables		1,028,277				998,912
Payments related to acquisitions, net of cash acquired		(1,108	)			(33,280	)
Payments related to investments		—				(15,000	)
Other investing activities		—				15,155
Net cash provided by investing activities		959,543				901,567
Financing activities:
Dividends paid		(98,333	)			(101,346	)
Repurchases of common stock		(229,508	)			(55,492	)
Payments on long-term debt		(36,000	)			(1,500	)
Draw on revolving credit		141,000				16,000
Other financing activities		6,936				15,854
Net cash used in financing activities		(215,905	)			(126,484	)
Effect of exchange rate changes on cash		533				(2,576	)
Net change in cash and cash equivalents		(45,207	)			17,655
Cash and cash equivalents at beginning of period		159,669				142,014
Cash and cash equivalents at end of period	$	114,462			$	159,669

PATTERSON COMPANIES, INC. SALES SUMMARY (Dollars in thousands) (Unaudited)
	April 27, 2024			April 29, 2023			Total Sales Growth		Foreign Exchange Impact		Net Interest Rate Swap		Acquisition Impact		Internal Sales Growth
Three Months Ended
Consolidated net sales
Consumable	$	1,376,634		$	1,333,446		3.2%		0.4%		—%		—%		2.8%
Equipment		249,071			279,901		(11.0)		—		—		—		(11.0)
Value-added services and other		96,955			107,805		(10.1)		0.3		5.3		—		(15.7)
Total	$	1,722,660		$	1,721,152		0.1%		0.3%		0.3%		—%		(0.5)%
Dental
Consumable	$	366,297		$	353,295		3.7%		—%		—%		—%		3.7%
Equipment		217,317			246,820		(12.0)		(0.1)		—		—		(11.9)
Value-added services and other		74,202			83,391		(11.0)		—		—		—		(11.0)
Total	$	657,816		$	683,506		(3.8)%		—%		—%		—%		(3.8)%
Animal Health
Consumable	$	1,010,337		$	980,151		3.1%		0.6%		—%		—%		2.5%
Equipment		31,754			33,081		(4.0)		—		—		—		(4.0)
Value-added services and other		22,089			18,946		16.6		1.6		—		—		15.0
Total	$	1,064,180		$	1,032,178		3.1%		0.6%		—%		—%		2.5%
Corporate
Value-added services and other	$	664		$	5,468		(87.9)%		—%		103.6%		—%		(191.5)%
Total	$	664		$	5,468		(87.9)%		—%		103.6%		—%		(191.5)%

PATTERSON COMPANIES, INC. SALES SUMMARY (Dollars in thousands) (Unaudited)
	April 27, 2024			April 29, 2023			Total Sales Growth		Foreign Exchange Impact		Net Interest Rate Swap		Acquisition Impact		Internal Sales Growth
Twelve Months Ended
Consolidated net sales
Consumable	$	5,274,012		$	5,147,330		2.5%		0.5%		—%		0.1%		1.9%
Equipment		888,597			950,403		(6.5)		(0.1)		—		—		(6.4)
Value-added services and other		405,663			373,738		8.5		0.4		0.7		3.7		3.7
Total	$	6,568,272		$	6,471,471		1.5%		0.4%		—%		0.3%		0.8%
Dental
Consumable	$	1,415,789		$	1,358,823		4.2%		(0.2)%		—%		—%		4.4%
Equipment		766,345			823,978		(7.0)		(0.1)		—		—		(6.9)
Value-added services and other		306,500			309,341		(0.9)		(0.1)		—		—		(0.8)
Total	$	2,488,634		$	2,492,142		(0.1)%		(0.1)%		—%		—%		—%
Animal Health
Consumable	$	3,858,223		$	3,788,507		1.8%		0.8%		—%		0.2%		0.8%
Equipment		122,252			126,425		(3.3)		—		—		—		(3.3)
Value-added services and other		86,594			49,990		73.2		3.1		—		27.5		42.6
Total	$	4,067,069		$	3,964,922		2.6%		0.8%		—%		0.5%		1.3%
Corporate
Value-added services and other	$	12,569		$	14,407		(12.8)%		—%		17.2%		—%		(30.0)%
Total	$	12,569		$	14,407		(12.8)%		—%		17.2%		—%		(30.0)%

PATTERSON COMPANIES, INC. OPERATING INCOME BY SEGMENT (In thousands) (Unaudited)
	Three Months Ended								Twelve Months Ended
	April 27, 2024				April 29, 2023				April 27, 2024				April 29, 2023
Operating income (loss)
Dental	$	62,230			$	79,121			$	209,807			$	237,268
Animal Health		50,934				46,622				139,077				126,994
Corporate		(25,377	)			(20,633	)			(95,960	)			(88,291	)
Total	$	87,787			$	105,110			$	252,924			$	275,971

PATTERSON COMPANIES, INC. RECONCILIATION OF GAAP TO NON-GAAP MEASURES (Dollars in thousands, except per share amounts) (Unaudited)
For the three months ended April 27, 2024		GAAP				Deal amortization				Interest rate swap				Non-GAAP
Net sales		$	1,722,660			$	—			$	6,360			$	1,729,020
Gross profit			371,155				—				6,360				377,515
Operating expenses			283,368				(9,655	)			—				273,713
Operating income			87,787				9,655				6,360				103,802
Other income (expense), net			(642	)			—				(6,360	)			(7,002	)
Income before taxes			87,145				9,655				—				96,800
Income tax expense			20,204				2,305				—				22,509
Net income			66,941				7,350				—				74,291
Net loss attributable to noncontrolling interests			(95	)			—				—				(95	)
Net income attributable to Patterson Companies, Inc.		$	67,036			$	7,350			$	—			$	74,386
Diluted earnings per share attributable to Patterson Companies, Inc.*		$	0.74			$	0.08			$	—			$	0.82
Gross margin			21.5	%											21.8	%
Operating margin			5.1	%											6.0	%
Effective tax rate			23.2	%											23.3	%
For the three months ended April 29, 2023		GAAP				Deal amortization				Interest rate swap				Non-GAAP
Net sales		$	1,721,152			$	—			$	693			$	1,721,845
Gross profit			389,761				—				693				390,454
Operating expenses			284,651				(9,772	)			—				274,879
Operating income			105,110				9,772				693				115,575
Other income (expense), net			(6,051	)			—				(693	)			(6,744	)
Income before taxes			99,059				9,772				—				108,831
Income tax expense			24,217				2,337				—				26,554
Net income			74,842				7,435				—				82,277
Net loss attributable to noncontrolling interests			(123	)			—				—				(123	)
Net income attributable to Patterson Companies, Inc.		$	74,965			$	7,435			$	—			$	82,400
Diluted earnings per share attributable to Patterson Companies, Inc.*		$	0.77			$	0.08			$	—			$	0.84
Gross margin			22.6	%											22.7	%
Operating margin			6.1	%											6.7	%
Effective tax rate			24.4	%											24.4	%
* May not sum due to rounding.

PATTERSON COMPANIES, INC. RECONCILIATION OF GAAP TO NON-GAAP MEASURES (Dollars in thousands, except per share amounts) (Unaudited)
For the twelve months ended April 27, 2024		GAAP				Deal amortization				Interest rate swap				Non-GAAP
Net sales		$	6,568,272			$	—			$	12,447			$	6,580,719
Gross profit			1,380,242				—				12,447				1,392,689
Operating expenses			1,127,318				(38,539	)			—				1,088,779
Operating income			252,924				38,539				12,447				303,910
Other income (expense), net			(9,871	)			—				(12,447	)			(22,318	)
Income before taxes			243,053				38,539				—				281,592
Income tax expense			57,534				9,218				—				66,752
Net income			185,519				29,321				—				214,840
Net loss attributable to noncontrolling interests			(412	)			—				—				(412	)
Net income attributable to Patterson Companies, Inc.		$	185,931			$	29,321			$	—			$	215,252
Diluted earnings per share attributable to Patterson Companies, Inc.*		$	1.98			$	0.31			$	—			$	2.30
Gross margin			21.0	%											21.2	%
Operating margin			3.9	%											4.6	%
Effective tax rate			23.7	%											23.7	%
For the twelve months ended April 29, 2023		GAAP				Deal amortization				Interest rate swap				Non-GAAP
Net sales		$	6,471,471			$	—			$	9,968			$	6,481,439
Gross profit			1,372,945				—				9,968				1,382,913
Operating expenses			1,096,974				(37,932	)			—				1,059,042
Operating income			275,971				37,932				9,968				323,871
Other income (expense), net			(5,810	)			—				(9,968	)			(15,778	)
Income before taxes			270,161				37,932				—				308,093
Income tax expense			63,563				9,083				—				72,646
Net income			206,598				28,849				—				235,447
Net loss attributable to noncontrolling interests			(959	)			—				—				(959	)
Net income attributable to Patterson Companies, Inc.		$	207,557			$	28,849			$	—			$	236,406
Diluted earnings per share attributable to Patterson Companies, Inc.*		$	2.12			$	0.29			$	—			$	2.42
Gross margin			21.2	%											21.3	%
Operating margin			4.3	%											5.0	%
Effective tax rate			23.5	%											23.6	%
* May not sum due to rounding.

PATTERSON COMPANIES, INC. FREE CASH FLOW (In thousands) (Unaudited)
	Twelve Months Ended
	April 27, 2024				April 29, 2023
Net cash used in operating activities	$	(789,378	)		$	(754,852	)
Additions to property and equipment and software		(67,626	)			(64,220	)
Collection of deferred purchase price receivables		1,028,277				998,912
Free cash flow	$	171,273			$	179,840

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240618970352/en/

INVESTOR CONTACT:

John M. Wright, Investor Relations

TEL: 651.686.1364

EMAIL: investor.relations@pattersoncompanies.com



MEDIA CONTACT:

Patterson Corporate Communications

TEL: 651.905.3349

EMAIL: corporate.communications@pattersoncompanies.com



WEB: pattersoncompanies.com

Source: Patterson Companies, Inc.

FAQ

What were Patterson Companies' fiscal 2024 Q4 net sales?

Patterson Companies reported Q4 net sales of $1.72 billion, a 0.1% increase year-over-year.

How did Patterson Companies' dental consumables perform in Q4 2024?

Dental consumables sales grew by 3.7% year-over-year in Q4 2024.

What was the impact of the cybersecurity attack on Patterson Companies' Q4 earnings?

The cybersecurity attack on Change Healthcare negatively impacted Q4 earnings by $0.04 per share.

What is the fiscal 2025 earnings guidance for Patterson Companies?

Patterson Companies projects fiscal 2025 GAAP earnings of $2.00 to $2.10 per share and adjusted earnings of $2.33 to $2.43 per share.

How much did Patterson Companies return to shareholders in fiscal 2024?

Patterson Companies returned $327.9 million to shareholders through dividends and share repurchases in fiscal 2024.

What were Patterson Companies' full-year 2024 net sales?

Full-year net sales for fiscal 2024 totaled $6.57 billion, a 1.5% increase year-over-year.